| Literature DB >> 34159210 |
Ding-Yu Wang1,2, Cassandra A Lee3, Yan-Zhang Li4, Bo Zhang4, Nan Li5, Dong Jiang1,2, Jia-Kuo Yu1,2.
Abstract
BACKGROUND: There is much room for improvement and optimization of meniscal allograft survivorship.Entities:
Keywords: ACL; cartilage; meniscal allograft transplant; osteotomy; prognostic factor; survivorship
Year: 2021 PMID: 34159210 PMCID: PMC8182187 DOI: 10.1177/23259671211007215
Source DB: PubMed Journal: Orthop J Sports Med ISSN: 2325-9671
Figure 1.Flow diagram of identification, screening, and selection of studies. MAT, meniscal allograft transplant.
Study Characteristics and Main Results of Included Studies
| Lead Author (Year) | Study Design, LOE | Sample Size, Patients/MAT | Age, y | Follow-up, y | Failure Definition | Failure, n | Survival Rate, 5 y/10 y | Independent Variables | Main Conclusion | Risk of Bias |
|---|---|---|---|---|---|---|---|---|---|---|
| Stevenson (2019)
| Case series, 4 | 67/73 | 34.31 ± 10.6 | 6.25 ± 4.3 (1-14.8) | Removal of autograft, knee arthroplasty, Lysholm score <65 | NM | 96/89.4 | Graft size | Worse outcome: undersized >5 mm (OR, 5.66;
| Moderate |
| Bloch (2019)
| Prospective cohort, 3 | 238/238 | 29 (13-55) | 3.4 (1-10) | Removal of autograft, knee arthroplasty | 25 | 87/82.1 | Severity of cartilage damage, type of cartilage damage, osteotomy, ACLR | Worse outcome: severe cartilage damage (ICRS score ≥3B vs
≤3A) ( | Low |
| Mahmoud (2018)
| Case series, 4 | 42/45 | 34.9 ± 10.6 | 8.6 ± 3.4 | Removal of autograft, knee arthroplasty | 8 | NM | Age, sex, side, knee compartment, severity of cartilage damage | Worse outcome: severe cartilage damage (Outerbridge grade
≥III vs ≤II) ( | Low |
| Kim (2018)
| Retrospective cohort, 3 | 208/214 | 33.6 ± 10.0 | >1 y | Revision, previous or concomitant relevant surgery | 11 | NM | Side, meniscal allograft horn position | Worse outcome: nonanatomic horn position (vs anatomic horn
position (OR, 3.88; | High |
| Saltzman (2018)
| Retrospective cohort, 3 | 40/40 | 26.10 ± 9.30 | 4.90 ± 2.30 (>2 y) | Removal of autograft, knee arthroplasty, revision | 4 | 87/NM | Tibial subchondral bone marrow lesion | NS: tibial subchondral bone marrow lesion | High |
| Lee (2017)
| Retrospective cohort, 3 | 222/222 | 34.1 ± 9.8 | 3.72 ± 1.64 | Removal of autograft, Lysholm score <65 | 25 | 83.5 | Age, sex, BMI, knee compartment, severity of cartilage damage, type of cartilage damage, time from prior meniscectomy | Worse outcome: higher age ( | Moderate |
| Zaffagnini (2016)
| Case series, 4 | 147/147 | 40.9 ± 11.2 (16.7-68.8) | 4.0 ± 1.9 (2.0-10.2) | Removal of autograft, knee arthroplasty, revision, Lysholm score <65 | SF, 7 | SF, 95/83 | Knee compartment | NS: knee compartment (SF, | Moderate |
| Van Der Straeten (2016)
| Case series, 4 | 313/329 | 33.3 (15-57) | 6.8 (0.2-24.3) | Removal of autograft, knee arthroplasty | 71 | NM | Age, sex, BMI, side, knee compartment, tobacco use, preservation method, severity of cartilage damage, ACLR, arthroscopy | Worse outcome: higher age (OR, 2.3; | Low |
| Parkinson (2016)
| Prospective cohort, 3 | 124/124 | 31 (8-49) | 3 (1-10) | Removal of autograft, knee arthroplasty, revision | 13 | 82/NA | Sex, knee compartment | Worse outcome: medial allograft ( | Low |
| Noyes (2016)
| Case series, 4 | 69/72 | 30 (14-49) | 11.2 ± 3.2 (>2 y) | Removal of autograft, knee arthroplasty, revision | 55 | 77/45 | Age, knee compartment, severity of cartilage damage, osteochondral autograft transfer | NS: age ( | Moderate |
| Waterman (2016)
| Case series, 4 | 227/230 | 27.2 ± 5.5 (18-46) | 2.14 | Total knee arthroplasty, revision | 59 | NM | Age, sex, tobacco use, ACLR or PCLR, osteotomy, surgeon | NS: age, sex, tobacco use, ACLR or PCLR, concomitant
osteotomy, lower volume surgeon ( | High |
| Ogura (2016)
| Case series, 4 | 17/18 | 31.7 ± 10.8 (16-56) | 7.9 ± 4.9 (2-16) | Knee arthroplasty, revision | 6 | 75/75 | Age, sex, type of cartilage damage, size of cartilage damage, sterilization | Better outcome: no sterilization ( | Moderate |
| Kazi (2015)
| Case series, 4 | 85/86 | Median, 40 (21-58) | Median, 15 (2.75-25.08) | Total knee arthroplasty | 24 | NM | Malalignment, correction of tibiofemoral angle | NS: concomitant osteotomy (medial/lateral)
( | Moderate |
| Faivre (2014)
| Case series, 4 | 23/23 | 27.4 | 5.28 (1.83-10.17) | Removal of autograft | 4 | NM | Arthroscopy | NS: arthroscopy (vs open surgery) ( | Moderate |
| McCormick (2014)
| Case series, 4 | 172/172 | 34.3 (16-56) | 4.92 (2-9.83) | Knee arthroplasty, revision | 8 | 95/NM | Knee compartment | NS: knee compartment ( | Moderate |
| Abat (2013)
| Prospective cohort, 2 | 88/88 | 37.3 (15-51) | 5 (2.5-10) | Removal of autograft | 5 | NM | Fixation technique | NS: fixation technique suture (fixation vs bony plug
fixation) ( | Moderate |
| Stone (2010)
| Case series, 4 | 115/119 | 46.9 (14.1-73.2) | 5.8 (0.2-12.3) | Removal of autograft, knee arthroplasty | 25 | 87.4 | Age, sex, knee compartment, severity of cartilage damage | Worse outcome: higher age (HR, 1.061; | Low |
| van Arkel (2002)
| Case series, 4 | 57/63 | 39 | 5 (0.3-8.4) | Lysholm score <65 | 13 | 78.2 | Knee compartment, ACL deficiency | Worse outcome: medial meniscal transplant
( | Low |
ACL, anterior cruciate ligament; ACLR, anterior cruciate ligament reconstruction; BMI, body mass index; CF, clinical failure; HR, hazard ratio; ICRS, International Cartilage Regeneration & Joint Preservation Society; LOE, level of evidence; MAT, meniscal allograft transplant; NA, not applicable; NM, not mentioned; NS, not significant; SF, surgical failure; OR, odds ratio; PCLR, posterior cruciate ligament reconstruction.
MAT sample size can exceed patient sample size, as some patients could have MAT in both legs or both medial and lateral MAT in a single leg.
Data are expressed as mean or mean ± SD (range) unless otherwise noted.
Estimated by data reported in the study.
Newcastle-Ottawa Scale Score of Included Studies From 2 Reviewers
| First Author (Year) | Study Design | Scale Item | Score | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| A | B | C | D | E | F | G | H | |||
| Stevenson (2019)
| Case series | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 5 |
| 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 5 | ||
| Bloch (2019)
| Cohort study | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 6 |
| 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 | ||
| Mahmoud (2018)
| Case series | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 8 | ||
| Kim (2018)
| Cohort study | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 3 |
| 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 3 | ||
| Saltzman (2018)
| Cohort study | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 3 |
| 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 3 | ||
| Lee (2017)
| Cohort study | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 6 |
| 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 6 | ||
| Zaffagnini (2016)
| Case series | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 6 |
| 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 6 | ||
| Van Der Straeten (2016)
| Case series | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 7 |
| 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 7 | ||
| Parkinson (2016)
| Case series | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 |
| 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 7 | ||
| Noyes (2016)
| Case series | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 6 |
| 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 6 | ||
| Waterman (2016)
| Case series | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 3 |
| 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 3 | ||
| Ogura (2016)
| Case series | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 5 |
| 0 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 5 | ||
| Kazi (2015)
| Case series | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 4 |
| 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 4 | ||
| Faivre (2014)
| Case series | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 6 |
| 0 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 5 | ||
| McCormick (2014)
| Case series | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 4 |
| 0 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 4 | ||
| Abat (2013)
| Cohort study | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 6 |
| 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 6 | ||
| Stone (2010)
| Case series | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 |
| 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 7 | ||
| van Arkel (2002)
| Case series | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 | ||
Item key:
A: Representativeness of the exposed cohort (1 = truly representative of the average population in the community)
B: Selection of controls (1 = drawn from the same community as the exposed cohort)
C: Ascertainment of exposure (1 = secure record [eg, surgical records] or structured interview)
D: Prospective study (1 = yes)
E: Control for additional factors (1 = study controls for any additional factor)
F: Assessment of outcome (1 = independent blind assessment or record linkage)
G: Sufficient follow-up duration (1 = yes)
H: Adequacy of follow-up (1 = complete follow-up [all patients accounted for] or patients lost to follow-up unlikely to introduce bias [small number lost])
Influence of Determinants on Survivorship of Meniscal Allograft
| Prognostic Factor | Significantly Worse | Not Significant | Evidence Synthesis |
|---|---|---|---|
| Patient characteristics | |||
| Age at meniscal allograft transplant | 2 LR
| 1 LR
| Conflicting |
| Sex | 4 LR
| Strong | |
| Body mass index | 1 LR
| Moderate | |
| Side affected | 2 LR
| Strong | |
| Knee compartment: medial (vs lateral) | 2 LR
| 3 LR
| Strong |
| Tobacco use | 1 LR
| Moderate | |
| Time from previous meniscectomy | 1 MR
| Limited | |
| Concomitant lesions and procedures | |||
| Full-thickness chondral lesion (vs partial-thickness lesion) | 3 LR
| 1 MR
| Strong |
| Full-thickness chondral kissing lesion (vs full-thickness lesion on single side) | 1 LR
| 1 MR
| Conflicting |
| Size of chondral lesion | 1 MR
| Limited | |
| Concomitant osteotomy for malalignment (vs normal alignment without osteotomy) | 1 LR
| 2 LR
| Strong |
| Concomitant ACL reconstruction (vs intact ACL without ACL reconstruction) | 2 LR
| Strong | |
| Tibial subchondral bone marrow lesion | 1 HR
| Limited | |
| Surgical factors | |||
| Arthroscopy (vs open surgery) | 1 LR
| Moderate | |
| Surgical technique: nonanatomic horn position (vs anatomic position) | 1 HR
| Limited | |
| Surgical technique: suture fixation (vs bony plug fixation) | 1 MR
| Limited | |
| Low-volume surgeons (vs high-volume surgeons) | 1 HR
| Limited | |
| Graft factors | |||
| Undersized allograft (vs matched or oversized allograft) | 1 MR
| Limited | |
| BioCleanse method (vs no sterilization) | 1 MR
| Limited | |
| Fresh-frozen allograft (vs viable allograft) | 1 LR
| Limited |
Data are presented as the number of studies for a given risk of bias and the associated reference numbers. BioCleanse manufacturer, Regeneration Technology Inc. ACL, anterior cruciate ligament; HR, high risk of bias; LR, low risk of bias; MR, moderate risk of bias.